Boston Scientific Corporation income statement BSX

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, Boston Scientific Corporation reported revenue of $20.1 billion, up 19.9% from the year before. Net income was $2.9 billion, a profit margin of 14.4%. Operating income came to $3.6 billion, an operating margin of 18.0%. Diluted earnings per share were $1.94. Over the twelve months ended Sep 30, 2026, revenue was $21.1 billion and net income was $3.5 billion. Across the 10 fiscal years shown, revenue grew from $8.4 billion in fiscal 2016 to $20.1 billion in fiscal 2025, about 10.2% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2026
Sep 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
FY 2019
Dec 31, 2019
FY 2018
Dec 31, 2018
FY 2017
Dec 31, 2017
FY 2016
Dec 31, 2016
Revenue
21,070
+8.9%
20,074
+19.9%
16,747
+17.6%
14,240
+12.3%
12,682
+6.7%
11,888
+19.9%
9,913
-7.7%
10,735
+9.3%
9,823
+8.6%
9,048
+7.9%
8,386
+12.2%
Cost of revenue
6,502
+7.0%
6,221
+18.3%
5,257
+21.0%
4,345
+9.8%
3,956
+6.6%
3,711
+7.1%
3,465
+11.2%
3,116
+10.8%
2,813
+8.5%
2,593
+7.0%
2,424
+11.6%
Gross profit
14,569
+9.8%
13,854
+20.6%
11,490
+16.1%
9,896
+13.4%
8,727
+6.7%
8,177
+26.8%
6,448
-15.4%
7,620
+8.7%
7,011
+8.6%
6,455
+8.3%
5,962
+12.4%
Selling, general and administrative
7,100
+6.5%
6,887
+15.1%
5,984
+15.3%
5,190
+14.8%
4,520
+3.7%
4,359
+15.1%
3,787
-3.9%
3,941
+10.4%
3,569
+8.3%
3,294
+6.3%
3,099
+7.9%
Restructuring and impairment
90
+1.1%
101
+531.2%
16
-76.8%
69
+187.5%
24
-40.0%
40
-23.1%
52
+36.8%
38
+5.6%
36
-2.7%
37
+32.1%
28
+7.7%
Operating income
3,932
+13.5%
3,613
+38.8%
2,603
+11.1%
2,343
+42.1%
1,649
+37.5%
1,199
+1598.8%
-80
-105.3%
1,518
+0.8%
1,506
+17.2%
1,285
+187.5%
447
+258.0%
Other non-operating income (expense)
-277
-43.5%
-228
+29.0%
-321
+10.3%
-358
+29.5%
-508
-333.0%
218
-39.8%
362
+201.1%
-358
-329.5%
156
+225.8%
-124
-235.1%
-37
+55.4%
Pretax income
3,655
+11.8%
3,385
+48.3%
2,282
+15.0%
1,985
+74.0%
1,141
+6.0%
1,076
+1462.0%
-79
-111.5%
687
-51.7%
1,422
+52.4%
933
+427.1%
177
+127.2%
Income tax
162
-66.7%
493
+13.1%
436
+10.9%
393
-11.3%
443
+1130.6%
36
+1700.0%
2
+100.0%
-4,013
-1511.6%
-249
-130.1%
828
+587.1%
-170
+58.6%
Net income
3,493
+25.5%
2,892
+56.7%
1,846
+16.0%
1,592
+128.1%
698
-32.9%
1,041
+1369.5%
-82
-101.7%
4,700
+181.3%
1,671
+1506.7%
104
-70.0%
347
+245.2%
Net income to common
3,502
+25.5%
2,898
+56.4%
1,853
+18.0%
1,570
+144.5%
642
-34.8%
985
+956.5%
-115
—
—
—
—
Basic EPS
2.38
+26.0%
1.96
+55.6%
1.26
+16.7%
1.08
+140.0%
0.45
-34.8%
0.69
+962.5%
-0.08
-102.4%
3.38
+179.3%
1.21
+1412.5%
0.08
-69.2%
0.26
+244.4%
Diluted EPS
2.37
+26.6%
1.94
+55.2%
1.25
+16.8%
1.07
+137.8%
0.45
-34.8%
0.69
+962.5%
-0.08
-102.4%
3.33
+179.8%
1.19
+1387.5%
0.08
-68.0%
0.25
+238.9%
Weighted average shares, basic
1,472
-0.4%
1,480
+0.6%
1,472
+1.3%
1,453
+1.6%
1,430
+0.6%
1,422
+0.4%
1,417
+1.8%
1,392
+0.8%
1,381
+0.8%
1,370
+0.9%
1,358
+1.2%
Weighted average shares, diluted
1,479
-0.9%
1,494
+0.6%
1,486
+1.5%
1,464
+1.7%
1,440
+0.4%
1,434
+1.2%
1,417
+0.4%
1,411
+0.7%
1,401
+0.6%
1,393
+1.1%
1,377
+2.7%
Other measures
Depreciation and amortization
1,432
+6.0%
1,368
+7.8%
1,269
+6.1%
1,196
+5.3%
1,136
+3.9%
1,093
-2.7%
1,123
+11.1%
1,011
+13.1%
894
+5.9%
844
+3.6%
815
+6.0%
EBITDA
5,364
+11.4%
4,981
+28.6%
3,872
+9.4%
3,539
+27.1%
2,785
+21.5%
2,292
+119.8%
1,043
-58.8%
2,529
+5.4%
2,400
+12.7%
2,129
+68.7%
1,262
+159.7%
Interest coverage
10.49x
10.35x
8.53x
8.84x
3.51x
3.52x
-0.22x
3.21x
6.25x
5.61x
1.92x
Margins
Gross margin
69.15%
69.01%
68.61%
69.49%
68.81%
68.78%
65.05%
70.98%
71.37%
71.34%
71.09%
Operating margin
18.66%
18.00%
15.54%
16.45%
13.00%
10.09%
-0.81%
14.14%
15.33%
14.20%
5.33%
Pretax margin
17.35%
16.86%
13.63%
13.94%
9.00%
9.05%
-0.80%
6.40%
14.48%
10.31%
2.11%
Profit margin
16.58%
14.41%
11.02%
11.18%
5.50%
8.76%
-0.83%
43.78%
17.01%
1.15%
4.14%
EBITDA margin
25.46%
24.81%
23.12%
24.85%
21.96%
19.28%
10.52%
23.56%
24.43%
23.53%
15.05%
Effective tax rate
4.43%
14.56%
19.11%
19.80%
38.83%
3.35%
—
-584.13%
-17.51%
88.75%
-96.05%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
BSX (NYSE)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Marlborough, MA
SEC filer status
Large accelerated filer
SEC CIK
885725

Other Surgical & Medical Instruments & Apparatus companies

All 151 Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.